Figure 3
From: Discovery of a highly selective JAK3 inhibitor for the treatment of rheumatoid arthritis
RB1 showed the irreversible inhibition of JAK3. Mass spectrometry mapping shows that Cys909 is modified by RB1. The MS/MS spectrum of peptide LVMEYLPSGCLR depicts the modification of Cys-909 by RB1 (marked by red colour).
